Literature DB >> 10796886

Production and release of endothelin-1 from the gut and spleen in portal hypertension due to cirrhosis.

N Nagasue1, D K Dhar, A Yamanoi, Y Emi, J Udagawa, A Yamamoto, M Tachibana, H Kubota, H Kohno, T Harada.   

Abstract

This study was aimed to evaluate the source of endothelin-1 (ET-1) in cirrhotic patients. ET-1 is implicated in the pathogenesis of portal hypertension. However, the mechanism and source for increased plasma ET-1 in cirrhotic patients are still obscure. Plasma ET-1 levels in systemic (SV), superior mesenteric (SMV), and splenic venous (SPV) blood were measured in 23 patients with cirrhosis and 8 controls with normal liver. Fourteen removed spleens were immunohistochemically studied for ET-1, CD34, CD68, and CD20. In situ hybridization was done to localize ET-1 messenger RNA (mRNA). In cirrhosis, ET-1 levels in both SMV and SPV were higher than in SV. ET-1 in SV and SPV were significantly higher in cirrhotic patients than in control patients. Three groups of cells in the spleen expressed both protein and mRNA of ET-1: endothelial cells in the sinus, which were also stained for CD34; cells in the germinal center; and cells in the marginal zone of lymphoid sheaths and follicles, which were also stained for CD20 but not for CD34 and CD68. The ET-1 concentration released from the spleen was in parallel with the grade of ET-1 expression in the spleen. The spleen is one of the major sites of ET-1 release in cirrhotic patients. Endothelial cells of the splenic sinus and possibly B lymphocytes in the germinal center and marginal zone of lymphoid sheaths and follicles seem to be the sites of ET-1 production in the spleen.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10796886     DOI: 10.1053/he.2000.6596

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  18 in total

Review 1.  Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension.

Authors:  H Reynaert; M G Thompson; T Thomas; A Geerts
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

2.  Portopulmonary hypertension in cirrhosis: the pathogenetic challenge.

Authors:  F Wong
Journal:  Gut       Date:  2005-02       Impact factor: 23.059

Review 3.  Role of endothelin in systemic and portal resistance in cirrhosis.

Authors:  P W Angus
Journal:  Gut       Date:  2006-09       Impact factor: 23.059

Review 4.  Portopulmonary hypertension.

Authors:  Michael Halank; Ralf Ewert; Hans-Juergen Seyfarth; Gert Hoeffken
Journal:  J Gastroenterol       Date:  2006-09       Impact factor: 7.527

5.  Hyperendothelinemia and ICG clearance in alcoholic and nonalcoholic cirrhosis.

Authors:  Shigeo Maruyama; Chisato Hirayama; Satoru Yamamoto; Masaharu Koda; Akihiro Udagawa; Yoshiro Kadowaki; Masayuki Inoue; Atsushi Sagayama; Kensuke Umeki
Journal:  Dig Dis Sci       Date:  2002-04       Impact factor: 3.199

6.  Successful treatment of portopulmonary hypertension with the selective endothelin receptor antagonist Sitaxentan.

Authors:  Christian M Kähler; Ivo Graziadei; Helene Vogelsinger; Susanna Desole; Katharina Cima; Wolfgang Vogel
Journal:  Wien Klin Wochenschr       Date:  2011-03-31       Impact factor: 1.704

7.  Relationship between abnormal characteristics of sublingual collateral and portal vein hemodynamic changes in patients with primary hepatic carcinoma.

Authors:  Wei-zhe Deng; Qing-bo Lang; Chang-quan Ling
Journal:  Chin J Integr Med       Date:  2008-06-21       Impact factor: 1.978

8.  Portopulmonary hypertension in decompensated cirrhosis with refractory ascites.

Authors:  F S Benjaminov; M Prentice; K W Sniderman; S Siu; P Liu; F Wong
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

9.  Endothelin and vascular function in liver disease.

Authors:  K Moore
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

10.  Effects of tumor necrosis factor, endothelin and nitric oxide on hyperdynamic circulation of rats with acute and chronic portal hypertension.

Authors:  Ji-Jian Wang; Gen-Wu Gao; Ren-Zhong Gao; Chang-An Liu; Xiong Ding; Zhen-Xiang Yao
Journal:  World J Gastroenterol       Date:  2004-03-01       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.